**Core Concept**
Idiopathic central precocious puberty (ICPP) is a condition where children experience premature activation of the hypothalamic-pituitary-gonadal axis, leading to early onset of puberty. The goal of treatment is to delay or stop the progression of puberty until a more appropriate age.

**Why the Correct Answer is Right**
The medication used to treat ICPP is a Gonadotropin-Releasing Hormone (GnRH) agonist. GnRH agonists initially stimulate the pituitary gland to release gonadotropins (LH and FSH), but with continuous administration, they downregulate GnRH receptors, leading to a decrease in gonadotropin secretion and subsequently, a decrease in sex hormone production. This effectively delays or stops the progression of puberty.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because Leuprolide is a GnRH agonist, but not the most commonly used one in the treatment of ICPP.
**Option B:** This option is incorrect because Spironolactone is an anti-androgen medication used in the treatment of certain endocrine disorders, but not in the treatment of ICPP.
**Option C:** This option is incorrect because Olanzapine is an atypical antipsychotic medication, and not used in the treatment of ICPP.

**Clinical Pearl / High-Yield Fact**
GnRH agonists are also used in the treatment of precocious puberty in children with disorders of sex development (DSD), and in the management of hormone-sensitive cancers.

**Correct Answer: C. Triptorelin**